
Watch our webinar on supervised learning of disease-associated cell states and dynamics
Webinar on the latest developments in the analysis of single-cell data, including from transcriptomic and imaging technologies.
Recent advances in single-cell technologies have opened the way for high-dimensional, high-throughput, and high-resolution measurements of biological systems. These methods enable capture of rare cell populations, which play a pivotal role in the initiation and progression of diseases such as cancer. However, the identification of such subpopulations and their studies in single-cell datasets remains challenging for data scientists.
On the 15th of March, Scailyte will host a webinar with Prof. Dr. Manfred Claassen, a co-founder of the company, who leads the Clinical Bioinformatics & Machine Learning in Translational Single-cell Biology group at University Hospital in Tübingen, Germany. During the webinar, Prof. Dr. M. Claassen will present his research and development of supervised machine learning techniques to study disease-associated cell states and dynamics in different types of single-cell data. The speaker will also highlight a power of multimodal single-cell data integration, such as imaging flow cytometry, in situ proteomic imaging and RNA-seq data, to achieve an unprecedented high precision in his studies of rare cell types and their pathologic behavior.
The format is the following:
- 5 mins – introduction
- 20 mins – main discussion
- 20 min+ – Q&A
Watch the webinar here: https://youtu.be/BGdYZ5Vy0wI
About Scailyte
Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets.
Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.
For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.
Recent News
Recent News
Future Labs Live 2023
Scailyte will be attending the Future Labs Live event, taking place from 31st May to 2nd June 2023 a...
Recent News
The psychological and economic impact of endometriosis
We're thrilled to present the third episode of Scailyte's Endometriosis Awareness Series, where Cinz...
Recent News
Jan Lichtenberg joins Scailyte's Board of Directors
Scailyte, a biomarker discovery company leveraging single-cell omics and artificial intelligence, is...
Recent News
Challenges and opportunities for innovation in Endometriosis
Join us for the second episode of the Endometriosis Awareness Series on “Challenges and opportunit...
Recent News
Swiss Biotech Day 2023
Sarah Carl will be a panellist at the Swiss Biotech Association's Swiss Biotech Day 2023 on April 24...
Recent News
Deciphering Disease Mechanisms Through Functional Genomics
Tiwari lab studies gene-epigenetic interplay in cell identity & its disruption in cancer/neurologica...
Recent News
Women's Health Innovation Summit
Exciting news from Scailyte! We are thrilled to announce that we have been selected among the top 15...
Recent News
ISCT 2023
Diana Stoycheva and Filipa Teixeira will be attending the ISCT 2023 Annual Meeting from 31st May to ...
Future Labs Live 2023
Scailyte will be attending the Future Labs Live event, taking place from 31st May to 2nd June 2023 a...
Recent News
The psychological and economic impact of endometriosis
We're thrilled to present the third episode of Scailyte's Endometriosis Awareness Series, where Cinz...
Jan Lichtenberg joins Scailyte's Board of Directors
Scailyte, a biomarker discovery company leveraging single-cell omics and artificial intelligence, is...
Recent News
Challenges and opportunities for innovation in Endometriosis
Join us for the second episode of the Endometriosis Awareness Series on “Challenges and opportunit...
Swiss Biotech Day 2023
Sarah Carl will be a panellist at the Swiss Biotech Association's Swiss Biotech Day 2023 on April 24...
Recent News
Deciphering Disease Mechanisms Through Functional Genomics
Tiwari lab studies gene-epigenetic interplay in cell identity & its disruption in cancer/neurologica...
Women's Health Innovation Summit
Exciting news from Scailyte! We are thrilled to announce that we have been selected among the top 15...